Table 4. Estimated risk of clopidogrel resistance in patients with at least one of the following risk factors: CYP2C19*2, CYP2C19*3, smoking, diabetes mellitus, increase in platelet count adjusted for age and sex.

Risk Factors	Adjusted OR*	95% CI	p-value†
*1/*1	1	-	-
*1/*1+Smoking	3.52	1.53–8.09	0.003
*1/*1+DM	3.33	1.62–6.85	0.001
*1/*1+Platelet	1.05	1.00–1.10	0.034
*1/*1+DM+Smoking	7.78	2.68–22.53	<0.001
*1/*1+DM+Platelet	3.26	1.65–6.45	0.001
*1/*1+DM+Smoking+Platelet	8.12	2.82–23.73	<0.001
*1/*2	2.94	1.65–5.26	<0.001
*2/*2	8.78	3.00–25.71	<0.001
*1/*3	11.26	2.47–51.41	0.002
*2/*3	33.15	7.01–156.72	<0.001
*1/*2+Smoking	7.43	2.76–20.05	<0.001
*2/*2+Smoking	22.03	5.44–89.17	<0.001
*1/*3+Smoking	28.06	4.84–162.83	<0.001
*2/*3+Smoking	83.16	12.51–552.97	<0.001
*1/*2+DM	9.19	3.59–23.52	<0.001
*2/*2+DM	27.23	6.90–107.37	<0.001
*1/*3+DM	34.68	6.75–178.06	<0.001
*2/*3+DM	102.77	17.16–615.29	<0.001
*1/*2+Platelet count	3.12	1.82–5.34	<0.001
*2/*2+Platelet count	9.23	3.15–27.03	<0.001
*1/*3+Platelet count	11.76	2.81–49.29	<0.001
*2/*3+Platelet count	34.86	7.30–166.45	<0.001
*1/*2+Smoking+DM	23.05	6.36–83.56	<0.001
*2/*2+Smoking+DM	68.3	12.96–360.05	<0.001
*1/*3+Smoking+DM	86.99	12.30–615.28	<0.001
*2/*3+Smoking+DM	257.79	31.21–2129.62	<0.001
*1/*2+Smoking+DM+Platelet	24.23	6.67–87.95	<0.001
*2/*2+Smoking+DM+Platelet	71.82	13.62–378.77	<0.001
*1/*3+Smoking+DM+Platelet	91.47	12.82–652.52	<0.001
*2/*3+Smoking+DM+Platelet	271.07	32.56–2256.56	<0.001

*Estimated OR for each risk factor category compared to men with no CYP2C19 mutation (wild type), with average age (66.25 year-old), average platelet count (255,900 platelets/mm³), who do not smoke and do not have diabetes. Platelet variable is calculated per ×1,000 platelet increased. Log odds for clopidogrel resistance were calculated using multivariate logistic regression as a function of CYP2C19*2+CYP2C19*3+Smoking+Diabetic Status+increased Platelet Count.

^†Risk is statistically significant when compared to the reference genotype at p-value<0.05.